Niche Product Portfolio AiPing Pharmaceutical specializes in a comprehensive range of generic prescription and OTC oral solid dose products, providing opportunities to expand into additional medication categories or formulations within the generics market.

Strategic Asset Sale The company sold significant assets to Shandong Xinhua Pharma in 2018, indicating a potential focus on core competencies and possibly opening avenues for new partnerships or joint ventures to leverage their remaining product lines.

Market Positioning With a revenue range of 1 to 10 million dollars and a dedicated presence in the US, AiPing is positioned as a growth opportunity for pharmaceutical distributors seeking to complement their portfolios with established US-based generic products.

Operational Capabilities AiPing’s global operations and emphasis on quality processes suggest readiness for expanded distribution channels, especially for clients looking to source compliant and quality-assured generics in the US market.

Technology & Compliance The company employs current technology stack elements focused on security and website functionality, highlighting its compliance-minded approach which could be appealing for partners prioritizing regulatory adherence and digital efficiency.